Dendritic cell immunization

BIOLOGICAL2 trials

Sponsors

M.D. Anderson Cancer Center, Oslo University Hospital

Conditions

GlioblastomaMelanoma

Phase 2

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Active, not recruitingNCT00338377

M.D. Anderson Cancer CenterMelanoma

Start: 2006-02-01End: 2030-02-28Updated: 2026-08-12

Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy

RecruitingNCT03548571

Oslo University HospitalGlioblastoma

Start: 2018-04-26End: 2026-05-01Target: 60Updated: 2024-04-03

Related Papers

Recent Advancements in Cell-Based Therapies in Melanoma.

2024-09-124 citations

Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors.

Journal of Clinical Oncology2023-06-014 citations

187 Multi-omic single-cell profiling demonstrates that competition for fatty acids and fatty acid oxidation enables tumor-infiltrating lymphocyte function and survival

Regular and Young Investigator Award Abstracts2021-11-01

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma

Journal for ImmunoTherapy of Cancer2021-05-0141 citations

311 Phase II trial of lymphodepletion plus adoptive cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma

Regular and Young Investigator Award Abstracts2020-11-012 citations

The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: An update from MD Anderson Cancer Center.

Journal of Clinical Oncology2017-03-011 citations